Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)
针对接受一线全身治疗后外周T细胞淋巴瘤患者的 JAK1 选择性抑制剂 golidocitinib 的 II 期多中心维持治疗研究 (JACKPOT26)
期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-026-01452-8
Wei, Juying; Cai, Qingqing; Zhang, Liling; Zou, Liqun; Li, Zengjun; Zhou, Keshu; Wu, Huijing; Qiu, Lihua; Su, Liping; Ding, Kaiyang; Zhou, Hui; Yu, Li; Li, Fei; Li, Wenyu; Lin, Li'e; Xiao, Qing; Wang, Erhua; Jing, Hongmei; Zheng, Meifang; Zhang, Hongyu; Gao, Yuhuan; Gao, Da; Chen, Lijia; Jin, Jie
JAK1
T细胞
JAK/STAT
淋巴瘤
T细胞
细胞生物学
免疫/内分泌
